Cullinan Therapeutics Inc. Common Stock (CGEM)
Stock · NASDAQ · Health Care
$12.91as of 10/16/2026
Price chart
Active signals
Resistance level
$17.25
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CGEM Signal Track Record
How signals performed across all stocks →What CGEM's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 44 | -2.4% | 41% | September 18, 2026 |
| Bollinger Band Breakdown | 23 | +2.4% | 61% | September 23, 2026 |
| Bollinger Band Breakout | 20 | -1.7% | 45% | August 11, 2026 |
| 200-Day Moving Average TouchActive now | 12 | -5.8% | 42% | September 29, 2026 |
| Any 20-session window (baseline) | -1.9% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CGEM
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecifi…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 109
- Website
- cullinantherapeutics.com/
Fundamentals
- 1-day range
- $13.46$14.18
- Market cap
- $1.10B
- P/E (trailing)
- —
- P/E (forward)
- -5.44
- EPS (trailing)
- $-3.41
- Dividend yield
- —
- Beta
- -0.03
- Avg. volume
- 881.1K
52-week range
$6.73$23.19
Next earnings: November 14, 2026 · EPS estimate $-0.84confirmed
How Cullinan Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2021 annual results
Source: 10-K filed Mar 17, 2022 · via SEC EDGAR / Finnhub
Operating Income-$67.95M(-359%)
Forecasts
11 analyst ratings
Buy 95%
Hold 5%
Sell 0%
1-year price forecast
High
$42
+225.5%
Median
$35
+171.2%
Low
$23
+78.2%
Cullinan Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CGEMCullinan Therapeutics Inc. Common Stock$12.93▼ 7.64%Market cap $1.10BP/E —$6.73$23.19
- REPLReplimune Group Inc. Common Stock$10.86▼ 7.57%Market cap $1.08BP/E —$1.5$16.33
- ODTXOdyssey Therapeutics Inc. Common Stock$17.17▼ 2.28%Market cap $1.04BP/E —$15.1$29.05
- MGTXMeiraGTx Holdings plc Ordinary Shares$9.28▼ 6.17%Market cap $1.18BP/E 11.93$6.62$15.35
- ALVOAlvotech Ordinary Shares$5▼ 5.84%Market cap $1.19BP/E —$2.94$9.05
- SANASana Biotechnology Inc. Common Stock$2.27▼ 8.28%Market cap $948.97MP/E —$2.32$6.55
- INBXInhibrx Biosciences Inc. Common Stock$89.83▼ 0.74%Market cap $1.26BP/E —$28.16$155.29
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CGEM Cullinan Therapeutics Inc. Common Stock | $1.10B | — | $12.93 | ▼ 7.64% | $6.73$23.19 |
| REPL Replimune Group Inc. Common Stock | $1.08B | — | $10.86 | ▼ 7.57% | $1.5$16.33 |
| ODTX Odyssey Therapeutics Inc. Common Stock | $1.04B | — | $17.17 | ▼ 2.28% | $15.1$29.05 |
| MGTX MeiraGTx Holdings plc Ordinary Shares | $1.18B | 11.93 | $9.28 | ▼ 6.17% | $6.62$15.35 |
| ALVO Alvotech Ordinary Shares | $1.19B | — | $5 | ▼ 5.84% | $2.94$9.05 |
| SANA Sana Biotechnology Inc. Common Stock | $948.97M | — | $2.27 | ▼ 8.28% | $2.32$6.55 |
| INBX Inhibrx Biosciences Inc. Common Stock | $1.26B | — | $89.83 | ▼ 0.74% | $28.16$155.29 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Cullinan Therapeutics Announces First Patient Dosed In Pivotal Phase 2 Study Of CLN-049 In Relapsed AML; Expects Phase 1 Update In Decemberbenzinga · 10/8/2026
- Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid LeukemiaYahoo · 10/8/2026
- HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $35 Price TargetBenzinga · 10/2/2026
- Reported Earlier, Cullinan Therapeutics Initiates NDA Submission For Zipalertinib Plus Chemotherapy In First-Line EGFR Exon 20 Insertion NSCLC Under FDA RTOR Program After Phase 3 REZILIENT3 Trial Met Primary EndpointBenzinga · 10/2/2026
- New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review ProgramYahoo · 10/1/2026
- Cullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune DiseasesSeekingAlpha · 9/29/2026
- Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049Yahoo · 9/28/2026
- Cullinan Therapeutics (CGEM) Expects Three T Cell Engager Data Readouts In Q4 2026Yahoo · 9/26/2026
- HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $35Benzinga · 9/25/2026
Insider Activity
Insider Actions →Acquired
169.1K
Disposed
46.2K
- Jennifer Michaelson · September 8, 2026 · Option Exercise4.0K @ $4.3
- Jennifer Michaelson · September 8, 2026 · Sale8.0K @ $21.57
- Jennifer Michaelson · August 13, 2026 · Option Exercise30.0K @ $4.3
- Jennifer Michaelson · August 13, 2026 · Sale30.0K @ $20.26
- Jennifer Michaelson · July 6, 2026 · Option Exercise4.0K @ $4.3
- Jennifer Michaelson · July 6, 2026 · Sale8.0K @ $17.82
- Jacquelyn L. Sumer · June 30, 2026 · Grant2.5K @ $8.6
- Mary Kay Fenton · June 30, 2026 · Grant1.5K @ $8.6
- Thistle Mary · June 16, 2026 · Grant25.3K
- Meek David D. · June 16, 2026 · Grant25.3K
- Rosenberg Anthony · June 16, 2026 · Grant25.3K
- Webster Stephen W · June 16, 2026 · Grant25.3K
- Allen Andrew R · June 16, 2026 · Grant21.8K
- Jennifer Michaelson · May 5, 2026 · Option Exercise4.0K @ $4.3
- Jennifer Michaelson · May 5, 2026 · Sale200 @ $15.58
Institutional Ownership
March 31, 2026
- Total shares held
- 64.57M
- Total value held
- $885.47M
- Institutional holders
- 167
Top holders this quarter
- Unknown8.96M
- Unknown7.65M
- Unknown5.75M
- Unknown4.45M
- Unknown3.11M
- Unknown2.54M
- Unknown2.48M
- Unknown2.03M
- Unknown1.91M
- Unknown1.71M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Cullinan delays arthritis data update to December
Cullinan Therapeutics announced it will delay its arthritis data update for zipalertinib to December due to ongoing safety concerns. This decision follows the release of strong Phase 3 lung cancer data, which initially saw the stock drop 18.2%. The company also confirmed plans for Q4 2026 updates across three T cell engager programs.
Cullinan delays arthritis data update to December. Cullinan Therapeutics announced it will delay its arthritis data update for zipalertinib to December due to ongoing safety concerns. This decision follows the release of strong Phase 3 lung cancer data, which initially saw the stock drop 18.2%. The company also confirmed plans for Q4 2026 updates across three T cell engager programs.